Vir Biotechnology (VIR) Times Interest Earned (2018 - 2026)
Vir Biotechnology (VIR) posted Times Interest Earned of -$193.12 for Q1 2026, up 91.94% sequentially from -$2396.0 in Q4 2025, and up 94.05% YoY from -$99.52 in Q1 2025.
Vir Biotechnology (VIR) Times Interest Earned (2018 - 2026) Analysis & Trends
Vir Biotechnology has reported Times Interest Earned for 9 years, with the latest figure at -$193.12 in Q1 2026.
- Quarterly Times Interest Earned rose 94.05% year-over-year to -$193.12 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$689.15 (up 95.42% YoY) and the FY2025 annual result came in at -$0.91, up 29.78% from the prior year.
- Times Interest Earned grew to -$193.12 in Q1 2026 per VIR's latest filing, from -$2396.0 in the prior quarter.
- Over five years, Times Interest Earned peaked at $5.5 in Q1 2022 and troughed at -$8566.8 in Q3 2024.
- A 5-year average of -$1644.7 and a median of -$156.24 in 2023 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2022 and 2025: Times Interest Earned surged 1104.94% in 2022, then slumped 927219.41% in 2025.
- Over 5 years, Times Interest Earned stood at -$0.74 in 2022, then surged by 47.04% to -$0.39 in 2023, then jumped by 33.68% to -$0.26 in 2024, then tumbled by 927219.41% to -$2396.0 in 2025, then soared by 91.94% to -$193.12 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$193.12, -$2396.0, and -$2588.7 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn | 43.06 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.06 |
| Mar 31, 2026 | -193.12 |
| Dec 31, 2025 | -2,396.05 |
| Sep 30, 2025 | -2,588.70 |
| Jun 30, 2025 | -2,234.28 |
| Mar 31, 2025 | -3,245.28 |
| Dec 31, 2024 | -0.26 |
| Sep 30, 2024 | -8,566.81 |
| Jun 30, 2024 | -127.41 |
| Mar 31, 2024 | -6,673.42 |
| Dec 31, 2023 | -0.39 |
| Sep 30, 2023 | -185.07 |
| Jun 30, 2023 | -108.79 |
| Dec 31, 2022 | -0.74 |
| Sep 30, 2022 | 1.09 |
| Jun 30, 2022 | -1.23 |
| Mar 31, 2022 | 5.50 |
| Dec 31, 2021 | 12.51 |
| Sep 30, 2021 | -0.29 |
| Jun 30, 2021 | 0.27 |